Review article: drug-induced liver injury in clinical practice

被引:93
|
作者
Bjornsson, E. [1 ]
机构
[1] Landspital Univ Hosp, Dept Internal Med, Sect Gastroenterol & Hepatol, IS-101 Reykjavik, Iceland
关键词
TERM-FOLLOW-UP; CAUSALITY ASSESSMENT; ACETAMINOPHEN HEPATOTOXICITY; CHRONIC HEPATITIS; PROGNOSTIC MARKERS; UNITED-STATES; DISEASE; CIRRHOSIS; JAUNDICE; FAILURE;
D O I
10.1111/j.1365-2036.2010.04320.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Drug-induced liver injury (DILI) is an important differential diagnosis in many patients in clinical hepatology. DILI is the leading cause of acute liver failure and is an important safety issue when new drugs are developed. Aims To provide a review of the recent data on DILI with particular focus on the most common and relevant issues seen in clinical practice. Methods A Medline search was undertaken to identify relevant literature using search terms including 'drug-induced liver injury' and 'hepatotoxicity'. Results The true incidence of DILI remains unknown but incidence up to 14 cases per 100 000 inhabitants and year has been reported. Antibiotics, analgesics and NSAIDs are the most common drugs causing liver injury. Idiosyncratic DILI has been shown to have a dose-dependent component and drugs without significant hepatic metabolism rarely cause DILI. Chronic elevation in liver enzymes can develop after DILI but this is rarely associated with clinical morbidity or mortality. Conclusions Drug-induced liver injury remains a diagnostic challenge. Multicentre studies and international collaborative work with well-characterized patients will increase our understanding of liver injury associated with drugs. New therapies for acute liver failure resulting from drugs are needed. Aliment Pharmacol Ther 2010; 32: 3-13
引用
收藏
页码:3 / 13
页数:11
相关论文
共 50 条
  • [1] Drug-induced liver injury: a clinical update
    Ghabril, Marwan
    Chalasani, Naga
    Bjornsson, Einar
    CURRENT OPINION IN GASTROENTEROLOGY, 2010, 26 (03) : 222 - 226
  • [2] The Natural History of Drug-Induced Liver Injury
    Bjornsson, Einar
    SEMINARS IN LIVER DISEASE, 2009, 29 (04) : 357 - 363
  • [3] Assessment of drug-induced liver injury in clinical practice
    Lucena, M. Isabel
    Garcia-Cortes, Miren
    Cueto, Raquel
    Lopez-Duran, J. L.
    Andrade, Raul J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 (02) : 141 - 158
  • [4] Drug-Induced Liver Injury in GI Practice
    Sandhu, Naemat
    Navarro, Victor
    HEPATOLOGY COMMUNICATIONS, 2020, 4 (05) : 631 - 645
  • [5] Drug-induced liver injury
    Bjornsson, Einar S.
    LAEKNABLADID, 2010, 96 (03): : 175 - 182
  • [6] EASL Clinical Practice Guidelines: Drug-induced liver injury
    Andrade, Raul J.
    Aithal, Guruprasad P.
    Bjornsson, Einar S.
    Kaplowitz, Neil
    Kullak-Ublick, Gerd A.
    Karlsen, Tom H.
    JOURNAL OF HEPATOLOGY, 2019, 70 (06) : 1222 - 1261
  • [7] Drug-induced liver injury: a safety review
    Garcia-Cortes, Miren
    Ortega-Alonso, Aida
    Lucena, M. Isabel
    Andrade, Raul J.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) : 795 - 804
  • [8] Drug-induced liver injury: a comprehensive review
    Hosack, Tom
    Damry, Djamil
    Biswas, Sujata
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [9] Rechallenge in drug-induced liver injury: the attractive hazard
    Andrade, Raul J.
    Robles, Mercedes
    Lucena, Maria Isabel
    EXPERT OPINION ON DRUG SAFETY, 2009, 8 (06) : 709 - 714
  • [10] Translating new knowledge on drug-induced liver injury into clinical practice
    Hernandez, Nelia
    Pontet, Yessica
    Bessone, Fernando
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (04) : 303 - 310